The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors
Moonjin Kim, Sujin Lee, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Won Ki Kang, Seung Tae Kim
Cancer Res Treat. 2016;48(1):153-161. Published online 2015 Mar 7 DOI: https://doi.org/10.4143/crt.2014.183
Citations to this article as recorded by 
Response heterogeneity as a new biomarker of treatment response in patients with neuroendocrine tumors
Clarisse Dromain, Marianne Pavel, Maxime Ronot, Niklaus Schaefer, Dalvinder Mandair, Delphine Gueguen, Catherine Cheng, Olivier Dehaene, Kathryn Schutte, David Cahané, Simon Jégou, Félix Balazard
Future Oncology.2023; 19(32): 2171. CrossRef
Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies
Lingaku Lee, Irene Ramos-Alvarez, Robert T. Jensen
Cancers.2022; 14(5): 1250. CrossRef
Volumetric 68Ga-DOTA-TATE PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with metastatic gastroenteropancreatic neuroendocrine tumors
Fiona OHLENDORF, Christoph HENKENBERENS, Thomas BRUNKHORST, Tobias L. ROSS, Hans CHRISTIANSEN, Frank M. BENGEL, Thorsten DERLIN
The Quarterly Journal of Nuclear Medicine and Molecular Imaging.2022;[Epub] CrossRef
Chromogranin A and serotonin for evaluation of treatment efficacy of neuroendocrine tumors
N. V. Lyubimova, Yu. S. Timofeev, T. K. Churikova, A. A. Markovich, G. S. Emelianova, I. S. Stilidi, N. E. Kushlinskii
Almanac of Clinical Medicine.2020; 47(8): 685. CrossRef
Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy
Daphne M. V. Huizing, Else A. Aalbersberg, Michelle W. J. Versleijen, Margot E. T. Tesselaar, Iris Walraven, Max J. Lahaye, Berlinda J. de Wit–van der Veen, Marcel P. M. Stokkel
Cancer Imaging.2020;[Epub] CrossRef
From Mouth to Brain: Neuroendocrine Markers Play as a Crosstalk Among Oral and Neurodegenerative Diseases
Marco Tatullo, Bruna Codispoti, Irina Makeeva, Caterina Benincasa, Gianrico Spagnuolo
Frontiers in Endocrinology.2019;[Epub] CrossRef
Ki-67 Index of 5% is Better Than 2% in Stratifying G1 and G2 of the World Health Organization Grading System in Pancreatic Neuroendocrine Tumors
Shao-Wei Gao, Chen-Song Huang, Xi-Tai Huang, Liu-Hua Chen, Wei Chen, Jian-Peng Cai, Xiao-Yu Yin
Pancreas.2019; 48(6): 795. CrossRef
Baseline plasma chromogranin A levels in patients with well-differentiated neuroendocrine tumors of the pancreas: A potential predictor of postoperative recurrence
Yoshihide Nanno, Hirochika Toyama, Ippei Matsumoto, Kyoko Otani, Sadaki Asari, Tadahiro Goto, Tetsuo Ajiki, Yoh Zen, Takumi Fukumoto, Yonson Ku
Pancreatology.2017; 17(2): 291. CrossRef
Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea
Kyong Joo Lee, Jae Hee Cho, Sang Hyub Lee, Si Young Song, Kwang Hyuk Lee, Seok Jeong, Ji Kon Ryu, Sang Myung Woo, Seungmin Bang, Jong Kyun Lee, Tae Hoon Lee, Woo Hyun Paik, Yong Tae Kim, Woo Jin Lee
Cancer Chemotherapy and Pharmacology.2017; 80(4): 799. CrossRef